HeartCore Q2 10-Q: $2.0M Net Loss, Going Concern Warning, Cash Down to $587K
HTCR sits 34% above its 52-week low of $2.01 on light trading volume (0.2× avg).
Summary
HeartCore's Q2 10-Q shows a $2.0M net loss, cash down to $587K, and a going concern warning. Revenue is concentrated in one customer, and the company is selling off remaining subsidiaries to raise cash.
Key Events · Earnings and Guidance · HTCR
-
Going Concern Warning
Management states substantial doubt about the company's ability to continue as a going concern, citing $0.6M cash, $0.6M working capital, and a $17.7M accumulated deficit as of June 30, 2026.
-
Q2 Net Loss of $2.0M
Net loss attributable to common shareholders was $2,042,436 for Q2 2026, compared to net income of $1,099,291 in Q2 2025. Revenue rose 71.6% to $321,428 but gross loss widened to $70,215.
-
Customer Concentration Risk
Customer A accounted for 74.6% of Q2 revenue and 100% of accounts receivable as of June 30, 2026. Loss of this customer would disproportionately impact revenue and cash flows.
-
Sigmaways Sale Closed for $1,000
The 51% stake in Sigmaways was sold on June 22, 2026 for $1,000 upfront plus up to $649,000 in earn-out, which management deems not probable of collection. A $423,496 loss on sale was recorded.
Analysis · HTCR · Technology
The Q2 10-Q confirms the losses previewed in today's 8-K and adds critical detail: cash has fallen to $587K, working capital is only $604K, and management explicitly states substantial doubt about the company's ability to continue as a going concern. The company is now highly dependent on one customer for 74.6% of revenue and 100% of receivables. The divestiture of Sigmaways closed for just $1,000 upfront, and the pending sale of HeartCore Luvina for ~$184K is expected to close by August 14, 2026. With an accumulated deficit of $17.7M and no near-term financing secured, the survival risk is acute.
At the time of this filing, HTCR was trading at $2.69 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $2.01 to $33.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.